


Stop (B) Partnership New Diagnostics Working Group



www.finddx.org
www.stoptb.org/wg/new_diagnostics/









 $6H \rightarrow 4R \rightarrow 3HP \rightarrow 1HP \rightarrow ?$



2017-2025



Tests for LTBI: What do we have?



New Diagnostics Working Group

Skin Test



RT-23

AJ Vaccines/SSI Laboratorio Nacional de Salud, Mexico Celltech Pharma S. A., Madrid, Spain

PPD-S2

Tubersol® (Sanofi Pasteur) Aplisol® (JHP Pharmaceuticals) PPD-s (Nihon BCG Seizo Co., Japan) PPD IC-65 (Cantacuzino Institute, Romania) PPD (SPAN diagnostics/Arkray Healthcare, India) PPD (Beijing Sanroad Biological





IGRAs


















Advansure™ TB-IGRA ELISA



New IGRA-like tests: Faster results - closer to patients

Stop (B) Partnership

New Diagnostics Working Group

QFT TB-Access



- Single tube incubation system
- Battery back up
- Qualitative result
- Up to 20 min read time
- Data stored on cartridge with identifier for connectivity
- Planned CE mark and launch 2020

Advansure™ i3 TB-IGRA



- Automated chemiluminescence immunoanalyzer-based IGRA
- Cartridge
- Quantitative result in 15m + incubation (Kim et al. Ann Lab Med 2020; 40(1): 33-39)

IP-10 release assay [r-biophorm®]







- Two platforms: ELISA and Lateral Flow
- Quantitative test based on alternative biomarker IP-10
- Automation support



- Multiple readers platforms
- **Automation support**




CFP-10

Specific skin tests: The 'IGRA in the skin'

Stop (B) Partnership

New Diagnostics Working Group









- Safety profile on par with PPD
- IGRA like specificity in BCG vaccinated
- High agreement with IGRA and correlation with exposure in contacts






NDWG task force on LTBI



New Diagnostics Working Group


- Conducting a SR to establish evidence for clinical performance of Specific Skin tests
- Study guidance document under development with NDWG, FIND, WHO to guide evidence generation for new IGRA like tests
- ■WHO will be looking at evidence from new LTBI tests as it emerges with a view to their role in preventive action





Going mobile with new digital tools for TB rule out after LTBI testing





LTBI care

a mobile app with dashboard to support programmatic management of LTBI





Portable battery driven CXR





FUJ!FILM









Artificial Intelligence based CXR interpretation in seconds













Remaining challenges in LTBI

Stop B Partnership

New Diagnostics Working Group



TB elimination requires a focus on LTBI



LTBI programs inevitably target healthy individuals



High NNT remains a major hurdle



Tests are imperfect in children and HIV infected, testing not a requirement in some settings



Country-level policy and practice

- infrastructure not established
- PPD shortages and supply chain issues

Drug*	Weekly Dosage	Maximum dose
Isoniazid	15 mg/kg rounded to nearest 50/100mg in patients ≥ 12 years	900 mg
	25 mg/kg rounded to the nearest 50/100 mg in patients 2-11 years	
Rifapentine (Priftin®)	10.0 - 14.0 kg = 300 mg	900 mg
	14.1 - 25.0 kg = 450 mg	
	25.1 - 32.0 kg = 600 mg	
	32.1 - 49.9 kg = 750 mg	

Test+treat remains expensive & rifapentine is often unavailable in LMIC



New Diagnostics Working Group



Acknowledgements

NDWG taskforce

Alberto Matteelli

Daniela Cirillo

Lele Rangaka

Maria Krutikov

Vlad Nikolayevskyy

Lena Faust

Rishi Gupta

Alexei Korobitsyn

Claudia Denkinger

FIND

Samuel Schumacher

Adam Penn-Nicholson

Kavi Ramjeet

Karishma Saran

SATVI

Mark Hatherill

Tom Scriba

Test manufacturers

for providing background and images

"An ounce of prevention is worth a pound of cure."

— Benjamin Franklin